M2 receptor antagonists(Muscarinic acetylcholine receptor M2 antagonists), M3 receptor antagonists(Muscarinic acetylcholine receptor M3 antagonists), mAChRs agonists(Muscarinic acetylcholine receptor agonists)

Therapeutic Areas

Urogenital Diseases

Active Indication-

Inactive Indication

Urinary Bladder, OveractiveUrinary Incontinence

Originator Organization

TheraVida, Inc.

Active Organization-

Inactive Organization

TheraVida, Inc.

SK Chemicals Co. Ltd.

Drug Highest PhaseDiscontinuedPhase 3

First Approval Date-

Regulation-

Structure

Molecular FormulaC26H37NO7

InChIKeyTWHNMSJGYKMTRB-KXYUELECSA-N

CAS Registry124937-52-6

View All Structures (2)

Clinical Trials associated with Pilocarpine/Tolterodine

NCT02485067 / CompletedPhase 3

Multicenter, Randomized, Double-blind, Parallel, Active Control, Phase III Clinical Study to Assess the Efficacy and Safety of THVD-201 in Patients With Overactive Bladder Including an Open-label, Extension Study

The primary purpose of this study is to assess the efficacy and safety of THVD-201(Combination of tolterodine and pilocarpine) in patients with Overactive bladder during the period of treatment, 12 weeks.
This study also includes an open label extension period of an additional 12 weeks following the treatment to assess long-term efficacy and safety of THVD-201 in patients with Overactive bladder.

Start Date01 Jan 2015

Sponsor / Collaborator

SK Chemicals Co. Ltd.

NCT01036035 / CompletedPhase 1

Effects of THVD-201 on Pharmacokinetics and Pharmacodynamics of Tolterodine in Healthy Subjects

THVD-201 is a novel combination of a muscarinic antagonist (tolterodine) and a muscarinic agonist (pilocarpine).

Start Date01 Sep 2009

Sponsor / Collaborator

TheraVida, Inc.

100 Clinical Results associated with Pilocarpine/Tolterodine

100 Translational Medicine associated with Pilocarpine/Tolterodine

100 Patents (Medical) associated with Pilocarpine/Tolterodine

Literatures (Medical) associated with Pilocarpine/Tolterodine

02 Jul 2016·Expert Opinion on PharmacotherapyQ3 · MEDICINE

Current and future pharmacotherapy for treating overactive bladder

Q3 · MEDICINE

Review

Author: Robinson, Dudley ; Thiagamoorthy, Ganesh ; Cardozo, Linda

INTRODUCTIONDrugs which prevent acetylcholine mediated involuntary detrusor contractions are the mainstay of overactive bladder(OAB) treatment but there are now several alternative therapeutic options available.AREAS COVEREDCurrent and future drug therapies for OAB are highlighted. These include novel antimuscarinic molecules (imidafenacin and tarafenacin); novel combination therapies with β3-adrenoceptor agonists or muscarinic agonists (tolenix) and a novel vaginal delivery method for oxybutynin. β3-adrenoceptor agonists(β3-AR) have been shown to be efficiacious in the management of OAB. The evidence supporting the first licensed β3-AR agonist, mirabegron, is assessed, as well as other putative β3-AR agonists in development such as solabegron, ritobegron, aryloxypropanolamine, TRK-380, and CL 316,243. The role of vaginal oestrogen is highlighted followed by a detailed analysis of botulinum-A toxin.EXPERT OPINIONAnticholinergics were the first OAB drug therapy on the market and have the largest dataset available. Despite obvious limitations, these are still first line medical therapy. There are a number of new OAB therapies under investigation and we await their contribution to the management armamentarium. Other novel drugs have been licenced and these are now vying for pole position in the treatment algorithm. One must exercise caution however until the long term effects of any new medicines are known.

01 Oct 2014·Expert Opinion on Investigational DrugsQ2 · MEDICINE

Phase II drugs that target cholinergic receptors for the treatment of overactive bladder

Q2 · MEDICINE

Review

Author: Ilias Giarenis ; Martino Maria Zacche ; Linda Cardozo

INTRODUCTIONOveractive bladder (OAB) is a term used to describe the symptom syndrome of urgency, with or without urgency incontinence, usually associated with frequency and nocturia. Antimuscarinics are the most widely prescribed class of drugs for OAB, although their systemic adverse effects limit their use in clinical practice as compliance. This has led to developments in the field.AREAS COVEREDIn this review, the authors describe Phase II drugs that target cholinergic receptors. First, the authors present the new antimuscarinics (tarafenacin and afacifenacin). This is followed by reports on a combination drug (tolenix) containing a muscarinic antagonist (tolterodine) associated with a muscarinic agonist (pilocarpine). Further, the authors discuss the trials of well-known drugs in either new combination therapy (solifenacin and mirabegron) or with new routes of delivery (oxybutynin vaginal ring). Finally, the authors examine the option of targeting nicotinic acetylcholine receptors (dexmecamylamine).EXPERT OPINIONDifferent strategies have been adopted to improve the efficacy and tolerability of therapeutics for OAB. Nicotinic receptors represent a novel therapeutic target; however, it is unlikely that antimuscarinic agents will be replaced as standard first-line therapy in the near future.

100 Deals associated with Pilocarpine/Tolterodine

R&D Status

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Urinary Bladder, Overactive	Phase 3	KR	SK Chemicals Co. Ltd.	01 Jan 2015
Urinary Bladder, Overactive	Phase 3	KR	SK Chemicals Co. Ltd.	01 Jan 2015
Urinary Incontinence	Phase 3	-	TheraVida, Inc.	01 Sep 2009

Clinical Result

Indication

Phase

Evaluation

View All Results

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis